ENDPOINTS

Forbion's new €75M fund; Cara Therapeutics to cut workforce after trial failure

10 months ago

News Briefing

A new obesity biotech; UroGen aims to raise $107M

10 months ago

News Briefing

Argenx drops post-Covid syndrome program; Mirum picks a dose for bile duct disease drug

10 months ago

News Briefing

Takeda signs option deal for TKI inhibitor; Enveda's $55M raise

11 months ago

News Briefing

Alzheon raises $100M; Regeneron ends mid-stage trial

11 months ago

News Briefing

ADC startup raises €30M; Cyrus Biotechnology to spin out Levitate Bio

11 months ago

News Briefing

Shionogi inks deal for preclinical hearing loss therapies; Alvotech’s refinancing pact

11 months ago

News Briefing

ArriVent inks ADC deal with Alphamab; Annexon's $125M offering

11 months ago

News Briefing

Corrected: Vilya raises $21M in Series A extension; Shionogi to open research center in San Diego

11 months ago

News Briefing

Novartis shares updated data for BTK inhibitor; Astellas resubmits BLA for cancer drug after CRL

11 months ago

News Briefing

Compugen, Nxera disclose milestone payments; Insmed aims for $650M offering

11 months ago

News Briefing

Insmed, Merus announce public offerings; AI startup raises $13M seed round

11 months ago

News Briefing

Agios sells rights to glioma drug to Royalty Pharma; Cargo’s $110M placement

11 months ago

News Briefing

#ASCO24: A roundup of the latest data from Merus, MorphoSys and others

11 months ago

R&D

ASCO abstracts are out, with data for ADCs, Nimbus' next-gen I/O drug and more

11 months ago

R&D

Pharma

Bicycle’s $555M placement; Tango Therapeutics scraps cancer program

11 months ago

News Briefing

Dyne's $305M offering; Nanobiotix delays Ph2 readout

11 months ago

News Briefing

Lyra to lay off 75% of its workers; Dupixent nears COPD decision

11 months ago

News Briefing

Foghorn’s $110M offering; Novovax investor withdraws proxy campaign

11 months ago

News Briefing

Monte Rosa’s $100M offering; Alexion to hand back preclinical program to Zealand Pharma

11 months ago

News Briefing

Adaptimmune’s debt financing deal; Tenaya to cut workers

12 months ago

News Briefing

Allogene's $110M offering; Apellis refinances

12 months ago

News Briefing

Deciphera had another bidder before Ono deal; Bristol Myers reports Ph3 fail in lung cancer

12 months ago

News Briefing

iTeos to raise $120M; Xbrane and STADA to out-license Lucentis biosimilar

Last year

R&D

News Briefing

about the author

author articles

Forbion's new €75M fund; Cara Therapeutics to cut workforce after trial failure

A new obesity biotech; UroGen aims to raise $107M

Argenx drops post-Covid syndrome program; Mirum picks a dose for bile duct disease drug

Takeda signs option deal for TKI inhibitor; Enveda's $55M raise

Alzheon raises $100M; Regeneron ends mid-stage trial

ADC startup raises €30M; Cyrus Biotechnology to spin out Levitate Bio

Shionogi inks deal for preclinical hearing loss therapies; Alvotech’s refinancing pact

ArriVent inks ADC deal with Alphamab; Annexon's $125M offering

Corrected: Vilya raises $21M in Series A extension; Shionogi to open research center in San Diego

Novartis shares updated data for BTK inhibitor; Astellas resubmits BLA for cancer drug after CRL

Compugen, Nxera disclose milestone payments; Insmed aims for $650M offering

Insmed, Merus announce public offerings; AI startup raises $13M seed round

Agios sells rights to glioma drug to Royalty Pharma; Cargo’s $110M placement

#ASCO24: A roundup of the latest data from Merus, MorphoSys and others

ASCO abstracts are out, with data for ADCs, Nimbus' next-gen I/O drug and more

Bicycle’s $555M placement; Tango Therapeutics scraps cancer program

Dyne's $305M offering; Nanobiotix delays Ph2 readout

Lyra to lay off 75% of its workers; Dupixent nears COPD decision

Foghorn’s $110M offering; Novovax investor withdraws proxy campaign

Monte Rosa’s $100M offering; Alexion to hand back preclinical program to Zealand Pharma

Adaptimmune’s debt financing deal; Tenaya to cut workers

Allogene's $110M offering; Apellis refinances

Deciphera had another bidder before Ono deal; Bristol Myers reports Ph3 fail in lung cancer

iTeos to raise $120M; Xbrane and STADA to out-license Lucentis biosimilar